These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

572 related items for PubMed ID: 23764350

  • 21. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
    Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G, SELECT study investigators.
    Lancet; 2013 Jun 22; 381(9884):2167-75. PubMed ID: 23562009
    [Abstract] [Full Text] [Related]

  • 22. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, CARE-MS I investigators.
    Lancet; 2012 Nov 24; 380(9856):1819-28. PubMed ID: 23122652
    [Abstract] [Full Text] [Related]

  • 23. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
    Miller DH, Weber T, Grove R, Wardell C, Horrigan J, Graff O, Atkinson G, Dua P, Yousry T, Macmanus D, Montalban X.
    Lancet Neurol; 2012 Feb 24; 11(2):131-9. PubMed ID: 22226929
    [Abstract] [Full Text] [Related]

  • 24. Siponimod for the treatment of secondary progressive multiple sclerosis.
    Dumitrescu L, Constantinescu CS, Tanasescu R.
    Expert Opin Pharmacother; 2019 Feb 24; 20(2):143-150. PubMed ID: 30517042
    [Abstract] [Full Text] [Related]

  • 25. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date.
    Gajofatto A.
    Drug Des Devel Ther; 2017 Feb 24; 11():3153-3157. PubMed ID: 29138536
    [Abstract] [Full Text] [Related]

  • 26. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
    Gold R, Piani-Meier D, Kappos L, Bar-Or A, Vermersch P, Giovannoni G, Fox RJ, Arnold DL, Benedict RHB, Penner IK, Rouyrre N, Kilaru A, Karlsson G, Ritter S, Dahlke F, Hach T, Cree BAC.
    J Neurol; 2022 Sep 24; 269(9):5093-5104. PubMed ID: 35639197
    [Abstract] [Full Text] [Related]

  • 27. Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod.
    Litwin T, Smoliński Ł, Członkowka A.
    Neurol Neurochir Pol; 2018 Sep 24; 52(1):98-101. PubMed ID: 29110882
    [Abstract] [Full Text] [Related]

  • 28. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Sep 24; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 29. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
    Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M, LAQ/5062 Study Group.
    Lancet; 2008 Jun 21; 371(9630):2085-92. PubMed ID: 18572078
    [Abstract] [Full Text] [Related]

  • 30. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
    Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH, Ustekinumab MS Investigators.
    Lancet Neurol; 2008 Sep 21; 7(9):796-804. PubMed ID: 18703004
    [Abstract] [Full Text] [Related]

  • 31. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group.
    Lancet Neurol; 2011 Jun 21; 10(6):520-9. PubMed ID: 21571593
    [Abstract] [Full Text] [Related]

  • 32. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
    Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI, SYNERGY study investigators.
    Lancet Neurol; 2019 Sep 21; 18(9):845-856. PubMed ID: 31285147
    [Abstract] [Full Text] [Related]

  • 33. Siponimod: First Global Approval.
    Al-Salama ZT.
    Drugs; 2019 Jun 21; 79(9):1009-1015. PubMed ID: 31144287
    [Abstract] [Full Text] [Related]

  • 34. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
    O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T, BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G.
    Lancet Neurol; 2009 Oct 21; 8(10):889-97. PubMed ID: 19729344
    [Abstract] [Full Text] [Related]

  • 35. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK.
    Lancet Haematol; 2015 Aug 21; 2(8):e315-25. PubMed ID: 26688484
    [Abstract] [Full Text] [Related]

  • 36. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M.
    Lancet Neurol; 2009 Jun 21; 8(6):519-29. PubMed ID: 19409854
    [Abstract] [Full Text] [Related]

  • 37. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
    Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, CARE-MS II investigators.
    Lancet; 2012 Nov 24; 380(9856):1829-39. PubMed ID: 23122650
    [Abstract] [Full Text] [Related]

  • 38. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.
    Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R.
    Lancet Neurol; 2016 Jan 24; 15(1):35-46. PubMed ID: 26621682
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
    Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN, BG-12 Phase IIb Study Investigators.
    Lancet; 2008 Oct 25; 372(9648):1463-72. PubMed ID: 18970976
    [Abstract] [Full Text] [Related]

  • 40. Oral fingolimod (FTY720) for relapsing multiple sclerosis.
    Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW, FTY720 D2201 Study Group.
    N Engl J Med; 2006 Sep 14; 355(11):1124-40. PubMed ID: 16971719
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.